Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Surgery Partners (SGRY) Common Equity (2016 - 2025)

Surgery Partners (SGRY) has disclosed Common Equity for 13 consecutive years, with $3.1 billion as the latest value for Q4 2025.

  • Quarterly Common Equity fell 2.04% to $3.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.1 billion through Dec 2025, down 2.04% year-over-year, with the annual reading at $3.1 billion for FY2025, 2.04% down from the prior year.
  • Common Equity hit $3.1 billion in Q4 2025 for Surgery Partners, up from $1.7 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $3.2 billion in Q4 2024 to a low of $1.1 billion in Q1 2021.
  • Historically, Common Equity has averaged $2.5 billion across 5 years, with a median of $3.0 billion in 2023.
  • Biggest five-year swings in Common Equity: skyrocketed 123.29% in 2021 and later crashed 44.42% in 2025.
  • Year by year, Common Equity stood at $2.0 billion in 2021, then surged by 49.31% to $2.9 billion in 2022, then grew by 3.18% to $3.0 billion in 2023, then grew by 5.34% to $3.2 billion in 2024, then dropped by 2.04% to $3.1 billion in 2025.
  • Business Quant data shows Common Equity for SGRY at $3.1 billion in Q4 2025, $1.7 billion in Q3 2025, and $3.2 billion in Q2 2025.